

26 February 2010

**Biofrontera announces that on February 24 it has published the audited annual statement for 2008**

**For further information please contact:**

Anke zur Mühlen  
Corporate Communication

+ 49 (0) 214 87632 22  
+ 49 (0) 214 87632 90  
a.zurmuehlen@biofrontera.com

Biofrontera AG  
Hemmelrather Weg 201  
D- 51377 Leverkusen, Germany

Leverkusen, Germany - Biofrontera (DSE: B8F) publishes that Warth & Klein AG Wirtschaftsprüfungsgesellschaft, the auditor appointed by Biofrontera's shareholder meeting, has granted the audit report for the finances of 2008 which had already been published in 2009. Previously the auditors could only announce the audit report since major finance and restructuring measures initiated by the company had not been fully completed.

In this respect the company has in the meantime reached the following goals, based on which the audit report has now been granted:

- Capital increase of over 7 mln. euro through the placement of new shares
- Restructuring of the convertible bond
- Based on these steps, a pronounced improvement of the equity capital
- Completion and payment of both phase III studies for the drug candidate BF-200 ALA
- Completion and payment of the phase II study of the drug candidate BF-derm1
- Market introduction of Belixos® cream for medical skin care accompanying therapy, f.i. in atopic dermatitis or psoriasis
- Cost reduction measures

Instantly following the completion of the auditing for 2008, the financial report of 2009 is being audited. Approval by the supervisory board is expected before the end of March 2010.

In the capital increases in 2009, new shares were generated which are currently listed on the Düsseldorf and Berlin trading floor (DE000A0XFUG4 und DE000A1CRN13), next to the original share class trading on the Düsseldorf regulated market, most other German stock markets and on Xetra (DE0006046113). To combine these three share classes in the regulated market, the company has last year mandated a bank, which is currently preparing the required prospectus together with a law firm and the Biofrontera management.

**About Biofrontera AG**

Biofrontera AG is specialized in the development of pharmaceutical products in the area of dermatology. The company is characterized by a broad, relatively close to the market product portfolio. Biofrontera is listed in the regulated market of the Düsseldorf stock exchange under the symbol B8F and the ISIN DE0006046113.

*This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the assumptions expressed or implied in this press release to be faulty. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on the forward-looking statements. Biofrontera AG disclaims any obligation to update these forward-looking statements to reflect future events or developments.*